On this page:

Treatment guidelines

Anthrax

• Oregon DHS Health Services Interim Guidelines— ambulatory care management of possible anthrax exposure (Oct. 29, 2001) (pdf) 192K
• Oregon State Public Health Laboratory anthrax testing guidelines for
  • clinical microbiology laboratories (Oct. 23, 2001) (pdf) 91K
  • environmental microbiology laboratories (Oct. 23, 2001) (pdf) 103K
• CDC Guidelines and Recommendations
  • Anthrax Vaccine Information Statements
  • Children and Anthrax: a fact sheet for clinicians
  • Update: Considerations for distinguishing influenza-like illness from inhalational anthrax MMWR, Nov. 9, 2001, Vol. 50, No. 44
  • Update: The anthrax investigations, and a description of adverse reactions associated with antimicrobial prophylaxis MMWR, Nov. 9, 2001, Vol. 50, No. 44
  • Update: Investigation of bioterrorism-related anthrax and interim guidelines for clinical evaluation of persons with possible anthrax MMWR, Nov. 2, 2001, Vol. 50, No. 43
  • Update: Updated Recommendations for antimicrobial prophylaxis among asymptomatic pregnant women after exposure to Bacillus anthracis MMWR, Nov. 2, 2001, Vol. 50, No. 43
  • CDC Update: Investigation of anthrax associated with intentional exposure and interim public health guidelines MMWR, Oct. 19, 2001, Vol. 50, No. 41
  • Recommendations for use of anthrax vaccine in the United States MMWR, December 15, 2000, Vol. 49, No. RR-15 (pdf) (224K)
  • Bioterrorism alleging use of anthrax and interim guidelines for management MMWR, February 5, 1999, Vol. 48, No. 4 (pdf) 269K
• Clinical presentation of inhalational anthrax following bioterrorism exposure: report of two surviving patients JAMA, Nov. 28, 2001, Vol. 286, No. 20
• Death due to bioterrorism-related inhalational anthrax: report of two patients JAMA, Nov. 28, 2001, Vol. 286, No. 20

---

Smallpox

• CDC smallpox hotline numbers
  • English —1-888-246-2675
  • Spanish —1-888-246-2857
  • TTY—1-866-874-2646
• CDC Guidelines
  • CDC clinical evaluation tool for smallpox vaccine adverse reactions
  • Smallpox vaccine methods and reactions poster (pdf) (3681 K, 11"x17")
  • Smallpox Response Plan and Guidelines (Sept. 2002)
  • Smallpox symptoms and treatment guidelines for clinicians (pdf)
  • Smallpox Vaccine Information Statements
  • Recommendations for use of vaccinia (smallpox) vaccine in the United States (pdf) MMWR, June 22, 2001, Vol. 50, No. RR-10 (927K)
• CDC Smallpox home page
• Oregon Public Health Division smallpox information

---

Other guidelines

• Acute Chemical Emergencies (NEJM, Feb. 19, 2004)
• Medical Treatment of Radiological Casualties (pdf) 334K
• Recognition of illness associated with exposure to chemical agents
• PHD Medical treatment chart for chemical warfare agents (pdf) 11"x17", 83K
• Recognition of illness associated with the intentional release of a biologic agent MMWR, Oct. 19, 2001, Vol. 50, No. 41
• Infection control guidelines for potential agents of bioterrorism (Adopted from: Layne, Chris. Bioterrorism; Infection Control Help.), Journal of Environmental Health, June 2000, Vol 62, No. 10, pp. 21-22 (pdf) 62K
• Bioterrorism response protocols for clinical laboratories
• The Medical Letter: articles on the clinical effects, prevention and treatment of injury caused by chemical biological and nuclear weapons
• Stanford University Medical Center links and treatment recommendations, including videos
• NW Center for Public Health Practice and Public Health bioterrorism training manual and presentation for primary care providers
• Bioterrorism on the home front: a new challenge for American medicine JAMA, Nov. 28, 2001, Vol. 286, No. 20
• Biological and chemical terrorism: strategic plan for preparedness and response
  MMWR, April 21, 2000, Vol. 49, No. RR-4 (pdf) 203K
• Improving local and state agency response to terrorist incidents involving biological weapons, U.S. Dept. of Defense, August, 2000 (pdf) 188K
• Oregon Public Health Division Guidelines for emergency responders